Core Viewpoint - STAAR Surgical Company has received a favorable recommendation from Institutional Shareholder Services regarding its merger with Alcon, urging stockholders to vote in favor of the amended merger agreement [1] Company Summary - STAAR Surgical Company is recognized as the global leader in phakic IOLs, specifically with its EVO family of Implantable Collamer® Lenses designed for vision correction [1] Industry Context - The recommendation from ISS reflects a positive outlook on the merger, which may influence shareholder sentiment and the overall market perception of STAAR's strategic direction [1]

Core Viewpoint - Broadwood Partners and its affiliates announced that Glass Lewis has reaffirmed its recommendation for STAAR Surgical Company shareholders to vote "AGAINST" the proposed acquisition by Alcon Inc. Glass Lewis concluded that there is no persuasive argument in favor of the acquisition [1] Group 1 - Glass Lewis is a leading independent proxy advisory firm [1] - The recommendation from Glass Lewis is based on their analysis of the proposed acquisition [1] - The report indicates a lack of compelling reasons to support the acquisition of STAAR by Alcon [1]

Core Viewpoint - STAAR Surgical Company is addressing misinformation regarding its go-shop process related to the pending merger with Alcon, emphasizing that claims made by Broadwood Partners about a credible buyer are false [1][2][5]. Go-Shop Process - The go-shop period lasted 30 days, during which STAAR engaged with 21 third parties, but only two signed a nondisclosure agreement (NDA) [3][4]. - FountainVest, allegedly the credible buyer mentioned by Broadwood, only reached out on day 21 of the go-shop period and did not show prior interest [3]. - STAAR's CEO responded promptly to FountainVest's inquiry, but the buyer delayed returning the NDA draft, which included a standstill provision [3][4]. - The go-shop period ended without any proposals received, and Broadwood's subsequent criticism of the process is viewed as an attempt to undermine STAAR's efforts [4][5]. Merger Details - The revised merger agreement with Alcon offers a cash price of $30.75 per share, representing a 74% premium to STAAR's 90-day volume-weighted average price [6][7]. - The merger is positioned as providing immediate value to stockholders compared to a longer, uncertain journey under Broadwood's influence [6]. Company Performance and Market Conditions - STAAR's CEO acknowledged challenges in growing procedure volumes in China, which have persisted into the fourth quarter [5]. - The company has experienced a significant slowdown in growth rates compared to the period from 2020 to 2023, but remains confident in long-term business growth [5]. Stockholder Engagement - A virtual Special Meeting of Stockholders is scheduled for December 19, 2025, to discuss the merger and allow stockholders to vote [7]. - Stockholders are encouraged to make informed decisions based on the facts presented regarding the merger with Alcon [6][7].

Core Viewpoint - Yunqi Capital Limited, holding a 5.1% stake in STAAR Surgical Company, has expressed strong opposition to Alcon Inc.'s revised acquisition offer of $30.75 per share, emphasizing that the sale process has been mishandled and does not maximize shareholder value [2][5][4]. Group 1: Acquisition Details - Alcon agreed to acquire STAAR Surgical for a total equity value of approximately $1.5 billion, which was later amended to $30.75 per share, raising the total equity value to approximately $1.6 billion [3]. - The revised purchase price represents an additional approximately $150 million in equity value for STAAR's stock [3]. Group 2: Shareholder Concerns - Broadwood Partners, owning a 30.2% stake in STAAR, criticized the sale process, stating that the new price is still roughly half of what Alcon offered in 2024, despite STAAR's projections remaining unchanged [4]. - Yunqi Capital believes it is not the right time to sell the company and argues that the sale process has been structured to favor Alcon, lacking transparency and failing to attract competitive bidders [5][6]. Group 3: Process Issues - The 30-day go-shop period was deemed too short for a credible market check for a global medical device company, with provisions that discouraged alternative buyers [6]. - STAAR reportedly contacted 21 parties, but Yunqi Capital claims the pool of potential buyers is significantly larger, indicating that the process may have deterred additional bidders [7]. Group 4: Market Performance - STAAR Surgical shares were down 5.65% at $23.95 at the time of publication, reflecting market concerns regarding the acquisition and the company's future prospects [8].

Group 1 - STAAR Surgical Company (STAA) received an acquisition offer from Alcon Inc. (ALC) in August for $28 per share, representing over a 50% premium to the prior share price [1] - The acquisition offer indicates a significant interest in STAAR Surgical by Alcon, suggesting potential growth opportunities in the ophthalmic device market [1] Group 2 - The article highlights the author's experience in analyzing undercovered companies, particularly in technology, software, electronics, and energy transition sectors [1] - The author emphasizes the importance of identifying asymmetric investment opportunities to achieve market-beating returns [1]

Core Points - Yunqi Capital Limited, an investment management firm and 5.1% shareholder of STAAR Surgical Company, has released a letter to STAAR shareholders regarding the closing of STAAR's go-shop period and the revised acquisition offer from Alcon Inc. for $30.75 per share [1] Group 1 - Yunqi Capital is advising STAAR shareholders on the recent developments concerning the acquisition offer from Alcon Inc. [1] - The acquisition offer from Alcon Inc. is set at $30.75 per share for STAAR Surgical Company [1]

Company Overview - STAAR Surgical specializes in the development, manufacture, and marketing of implantable lenses for the eye, primarily used in refractive surgery to improve vision [1] - The company competes with other players in the ophthalmic industry, including Alcon and Bausch + Lomb [1] Stock Performance - As of the latest data, STAA is priced at $25.59, reflecting an increase of 8.71% or $2.05 [4] - The stock has shown significant volatility, with a trading range over the past year between $13.50 and $30.81 [6] - During the trading day, the stock fluctuated between a low of $25.09 and a high of $27.50 [4] Market Outlook - John Young from Canaccord Genuity has set a price target of $30.75 for STAA, indicating a potential increase of about 18.77% from its current price [2][6] - The stock has been upgraded to a Zacks Rank 2 (Buy), reflecting increased optimism about STAAR Surgical's earnings prospects [3][6] - STAAR Surgical has a market capitalization of approximately $1.27 billion, indicating its size in the market [5] - The trading volume for the day is 5.54 million shares, reflecting strong investor interest [5]

Investors might want to bet on Staar Surgical (STAA) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earni ...

Core Viewpoint - Broadwood Partners, which owns 30.2% of STAAR Surgical Company, opposes the proposed acquisition by Alcon Inc., claiming the sale process was flawed and the offered price inadequate [1][6]. Group 1: Sale Process and Board Actions - The STAAR Board is accused of running a flawed sale process, ignoring buyout interest from multiple parties, and negotiating exclusively with Alcon, with whom the Chair had a prior relationship [3][4]. - Shareholders were prepared to reject the transaction, but the Board postponed the vote multiple times and attempted to implement a go-shop mechanism that failed to attract competitive bids [4][5]. - The Board's claims regarding the fairness of the sale process and the compensation packages for executives have been challenged, with Broadwood asserting that these claims were misleading [2][5]. Group 2: Financial Aspects and Shareholder Concerns - Alcon's initial offer of $28 per share was criticized as inadequate, especially after it later increased the offer by $150 million due to shareholder pressure [5][6]. - Concerns were raised about the substantial financial incentives for STAAR's executives, particularly the CEO's potential $24 million payout for a short tenure, which could compromise the integrity of the sale process [5][6]. - Broadwood believes that STAAR's true value exceeds $30.75 per share, suggesting that a properly structured competitive process could yield a higher offer from Alcon [7]. Group 3: Future Outlook and Shareholder Actions - Broadwood expresses confidence in STAAR's future as an independent company, anticipating it could become one of the most profitable medical technology firms if management's projections are met [7]. - Broadwood intends to vote against the revised transaction and encourages other shareholders to do the same, emphasizing the need for a more credible Board to maximize shareholder value [8].

智通财经获悉，周二，STAAR Surgical(STAA.US)盘前大涨超15%，报27.15美元。消息面上，Alcon表 示，已将其收购 STAAR Surgical 的报价提高到约 16 亿美元的总股权价值，高于此前的 15 亿美元。根 据修订后的协议条款，Alcon 将以每股 30.75 美元的价格现金购买所有 STAAR Surgical 的流通股，高于 此前每股 28 美元的报价。Alcon 表示，这笔交易现在较 STAAR 过去 90 日的成交量加权平均价格溢价 74%，较 8 月 4 日(即合并宣布前一天)STAAR 股票的收盘价溢价 66%。 本文源自：智通财经网 ...